Good clinical outcomes following transjugular intrahepatic portosystemic stent‐shunts in Budd–Chiari syndrome
Alimentary Pharmacology & Therapeutics2014Vol. 39(8), pp. 864–872
Citations Over TimeTop 10% of 2014 papers
Dhiraj Tripathi, Ross MacNicholas, Chirag Kothari, L. Sunderraj, H. Al‐Hilou, Bharath Rangarajan, Frederick Chen, K. Mangat, Elwyn Elias, Simon Olliff
Abstract
Long-term outcomes following TIPSS for Budd-Chiari syndrome are very good. PTFE-covered stents have significantly better primary patency. The value of prognostic scores is controversial. TIPSS should be considered as first line therapy in symptomatic patients in whom hepatic vein patency cannot be restored.
Related Papers
- → Transjugular intrahepatic portosystemic shunt in the management of Budd Chiari syndrome(2006)32 cited
- → Hepatic encephalopathy and survival after transjugular intrahepatic portosystemic shunt: Do spontaneous portosystemic shunts matter?(2023)2 cited
- → Refractory portal hypertension complications successfully managed by parallel transjugular intrahepatic portosystemic shunt (TIPS): a case report(2022)1 cited
- → Transjugular Intrahepatic Portosystemic Shunt is effective to treat portal hypertension due to sinusoidal obstructive syndrome(2023)1 cited
- → Modified Transjugular Intrahepatic Portosystemic Shunt in the Treatment of Budd-Chiari Syndrome(2008)